234 related articles for article (PubMed ID: 22944772)
1. Discovery of N6-phenyl-1H-pyrazolo[3,4-d]pyrimidine-3,6-diamine derivatives as novel CK1 inhibitors using common-feature pharmacophore model based virtual screening and hit-to-lead optimization.
Yang LL; Li GB; Yan HX; Sun QZ; Ma S; Ji P; Wang ZR; Feng S; Zou J; Yang SY
Eur J Med Chem; 2012 Oct; 56():30-8. PubMed ID: 22944772
[TBL] [Abstract][Full Text] [Related]
2. Structure-activity relationship studies of pyrazolo[3,4-d]pyrimidine derivatives leading to the discovery of a novel multikinase inhibitor that potently inhibits FLT3 and VEGFR2 and evaluation of its activity against acute myeloid leukemia in vitro and in vivo.
Yang LL; Li GB; Ma S; Zou C; Zhou S; Sun QZ; Cheng C; Chen X; Wang LJ; Feng S; Li LL; Yang SY
J Med Chem; 2013 Feb; 56(4):1641-55. PubMed ID: 23362959
[TBL] [Abstract][Full Text] [Related]
3. A hit to lead discovery of novel N-methylated imidazolo-, pyrrolo-, and pyrazolo-pyrimidines as potent and selective mTOR inhibitors.
Lee W; Ortwine DF; Bergeron P; Lau K; Lin L; Malek S; Nonomiya J; Pei Z; Robarge KD; Schmidt S; Sideris S; Lyssikatos JP
Bioorg Med Chem Lett; 2013 Sep; 23(18):5097-104. PubMed ID: 23932790
[TBL] [Abstract][Full Text] [Related]
4. Anhydrous versus hydrated N4-substituted 1H-pyrazolo[3,4-d]pyrimidine-4,6-diamines: hydrogen bonding in two and three dimensions.
Trilleras J; Quiroga J; Cobo J; Marchal A; Nogueras M; Low JN; Glidewell C
Acta Crystallogr B; 2008 Oct; 64(Pt 5):610-22. PubMed ID: 18799849
[TBL] [Abstract][Full Text] [Related]
5. The discovery and optimisation of pyrido[2,3-d]pyrimidine-2,4-diamines as potent and selective inhibitors of mTOR kinase.
Malagu K; Duggan H; Menear K; Hummersone M; Gomez S; Bailey C; Edwards P; Drzewiecki J; Leroux F; Quesada MJ; Hermann G; Maine S; Molyneaux CA; Le Gall A; Pullen J; Hickson I; Smith L; Maguire S; Martin N; Smith G; Pass M
Bioorg Med Chem Lett; 2009 Oct; 19(20):5950-3. PubMed ID: 19762236
[TBL] [Abstract][Full Text] [Related]
6. 7-Phenyl-pyrido[2,3-d]pyrimidine-2,4-diamines: novel and highly selective protein tyrosine phosphatase 1B inhibitors.
Cheung AW; Banner B; Bose J; Kim K; Li S; Marcopulos N; Orzechowski L; Sergi JA; Thakkar KC; Wang BB; Yun W; Zwingelstein C; Berthel S; Olivier AR
Bioorg Med Chem Lett; 2012 Dec; 22(24):7518-22. PubMed ID: 23122867
[TBL] [Abstract][Full Text] [Related]
7. Discovery of potent and selective thienopyrimidine inhibitors of Aurora kinases.
McClellan WJ; Dai Y; Abad-Zapatero C; Albert DH; Bouska JJ; Glaser KB; Magoc TJ; Marcotte PA; Osterling DJ; Stewart KD; Davidsen SK; Michaelides MR
Bioorg Med Chem Lett; 2011 Sep; 21(18):5620-4. PubMed ID: 21778056
[TBL] [Abstract][Full Text] [Related]
8. 2-Phenylamino-6-cyano-1H-benzimidazole-based isoform selective casein kinase 1 gamma (CK1γ) inhibitors.
Hua Z; Huang X; Bregman H; Chakka N; DiMauro EF; Doherty EM; Goldstein J; Gunaydin H; Huang H; Mercede S; Newcomb J; Patel VF; Turci SM; Yan J; Wilson C; Martin MW
Bioorg Med Chem Lett; 2012 Sep; 22(17):5392-5. PubMed ID: 22877629
[TBL] [Abstract][Full Text] [Related]
9. Discovery of potent and selective inhibitors of the mammalian target of rapamycin (mTOR) kinase.
Nowak P; Cole DC; Brooijmans N; Bursavich MG; Curran KJ; Ellingboe JW; Gibbons JJ; Hollander I; Hu Y; Kaplan J; Malwitz DJ; Toral-Barza L; Verheijen JC; Zask A; Zhang WG; Yu K
J Med Chem; 2009 Nov; 52(22):7081-9. PubMed ID: 19848404
[TBL] [Abstract][Full Text] [Related]
10. Discovery of 4-morpholino-6-aryl-1H-pyrazolo[3,4-d]pyrimidines as highly potent and selective ATP-competitive inhibitors of the mammalian target of rapamycin (mTOR): optimization of the 6-aryl substituent.
Verheijen JC; Richard DJ; Curran K; Kaplan J; Lefever M; Nowak P; Malwitz DJ; Brooijmans N; Toral-Barza L; Zhang WG; Lucas J; Hollander I; Ayral-Kaloustian S; Mansour TS; Yu K; Zask A
J Med Chem; 2009 Dec; 52(24):8010-24. PubMed ID: 19894727
[TBL] [Abstract][Full Text] [Related]
11. Discovery of pyrazolo[1,5-a]pyrimidine-based Pim inhibitors: a template-based approach.
Dwyer MP; Keertikar K; Paruch K; Alvarez C; Labroli M; Poker C; Fischmann TO; Mayer-Ezell R; Bond R; Wang Y; Azevedo R; Guzi TJ
Bioorg Med Chem Lett; 2013 Nov; 23(22):6178-82. PubMed ID: 24091081
[TBL] [Abstract][Full Text] [Related]
12. 2-Aminopyrazolo[1,5-a]pyrimidines as potent and selective inhibitors of JAK2.
Ledeboer MW; Pierce AC; Duffy JP; Gao H; Messersmith D; Salituro FG; Nanthakumar S; Come J; Zuccola HJ; Swenson L; Shlyakter D; Mahajan S; Hoock T; Fan B; Tsai WJ; Kolaczkowski E; Carrier S; Hogan JK; Zessis R; Pazhanisamy S; Bennani YL
Bioorg Med Chem Lett; 2009 Dec; 19(23):6529-33. PubMed ID: 19857967
[TBL] [Abstract][Full Text] [Related]
13. Discovery and hit-to-lead optimization of 2,6-diaminopyrimidine inhibitors of interleukin-1 receptor-associated kinase 4.
McElroy WT; Michael Seganish W; Jason Herr R; Harding J; Yang J; Yet L; Komanduri V; Prakash KC; Lavey B; Tulshian D; Greenlee WJ; Sondey C; Fischmann TO; Niu X
Bioorg Med Chem Lett; 2015 May; 25(9):1836-41. PubMed ID: 25870132
[TBL] [Abstract][Full Text] [Related]
14. Discovery of highly potent and selective type I B-Raf kinase inhibitors.
Wang X; Berger DM; Salaski EJ; Torres N; Hu Y; Levin JI; Powell D; Wojciechowicz D; Collins K; Frommer E
Bioorg Med Chem Lett; 2009 Dec; 19(23):6571-4. PubMed ID: 19854649
[TBL] [Abstract][Full Text] [Related]
15. Discovery and in vitro evaluation of potent kinase inhibitors: Pyrido[1',2':1,5]pyrazolo[3,4-d]pyrimidines.
Alberti MJ; Auten EP; Lackey KE; McDonald OB; Wood ER; Preugschat F; Cutler GJ; Kane-Carson L; Liu W; Jung DK
Bioorg Med Chem Lett; 2005 Aug; 15(16):3778-81. PubMed ID: 15993060
[TBL] [Abstract][Full Text] [Related]
16. B-Raf kinase inhibitors: hit enrichment through scaffold hopping.
Gopalsamy A; Shi M; Hu Y; Lee F; Feldberg L; Frommer E; Kim S; Collins K; Wojciechowicz D; Mallon R
Bioorg Med Chem Lett; 2010 Apr; 20(8):2431-4. PubMed ID: 20307980
[TBL] [Abstract][Full Text] [Related]
17. Synthesis, anticancer and radioprotective activities of some new pyrazolo[3,4-d]pyrimidines containing amino acid moieties.
Ghorab MM; Ragab FA; Noaman E; Heiba HI; Aboulmagd SA
Arzneimittelforschung; 2009; 59(2):96-103. PubMed ID: 19338140
[TBL] [Abstract][Full Text] [Related]
18. Discovery of novel thieno[2,3-d]pyrimidin-4-yl hydrazone-based inhibitors of Cyclin D1-CDK4: synthesis, biological evaluation, and structure-activity relationships.
Horiuchi T; Chiba J; Uoto K; Soga T
Bioorg Med Chem Lett; 2009 Jan; 19(2):305-8. PubMed ID: 19091560
[TBL] [Abstract][Full Text] [Related]
19. Discovery of potent and selective pyrazolopyrimidine janus kinase 2 inhibitors.
Hanan EJ; van Abbema A; Barrett K; Blair WS; Blaney J; Chang C; Eigenbrot C; Flynn S; Gibbons P; Hurley CA; Kenny JR; Kulagowski J; Lee L; Magnuson SR; Morris C; Murray J; Pastor RM; Rawson T; Siu M; Ultsch M; Zhou A; Sampath D; Lyssikatos JP
J Med Chem; 2012 Nov; 55(22):10090-107. PubMed ID: 23061660
[TBL] [Abstract][Full Text] [Related]
20. Pyrazolo-pyrimidines: a novel heterocyclic scaffold for potent and selective p38 alpha inhibitors.
Das J; Moquin RV; Pitt S; Zhang R; Shen DR; McIntyre KW; Gillooly K; Doweyko AM; Sack JS; Zhang H; Kiefer SE; Kish K; McKinnon M; Barrish JC; Dodd JH; Schieven GL; Leftheris K
Bioorg Med Chem Lett; 2008 Apr; 18(8):2652-7. PubMed ID: 18359226
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
